english.prescrire.org > Prescrire International > N°137 - April 2013

n°137

April 2013

Issue Contents
Editorial

Free  ADR: a new global phenomenon, thanks to the ICH

p.88
The effects of the Agency for Drug Reconciliation will be felt worldwide

New Products


Bismuth + metronidazole + tetracycline (New Combination)

p.89-92
Why risk adding bismuth?

Bismuth encephalopathy: a brief history

p.92

Ruxolitinib (New Drug)

p.93
Bone marrow fibrosis: theory versus practice

Adverse Effects


Drugs that delay wound healing

p.94-98
Bleeding, seepage

Natural healing of skin wounds

p.95

Digoxin and breast cancer

p.98
Plausible risk

Reviews


Deep venous thrombosis and pulmonary embolism

p.99-104
Part 1 - Initial treatment: usually a low-molecular-weight heparin

Anticoagulants and their adverse effects

p.102-103

Outlook


Free  New drugs and indications in 2012

p.105-107
Sluggish progress, timid measures to protect patients

Free  Prescrire's ratings of new products and indications over the last 10 years

p.106

Free  Drug policy: maintain pressure on the authorities

p.107

Free  Towards better patient care: drugs to avoid

p.108-111
Patients and healthcare professionals should reassess ongoing treatments

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe